Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Epstein-Barr virus latent membrane protein 2 (LMP2) peptide-human leukocyte antigen (HLA) complex is a major histocompatibility complex (MHC) class I-restricted target presented on the surface of cells infected with Epstein-Barr virus (EBV). LMP2 is a viral latency II protein expressed in several EBV-associated malignancies, including nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, Burkitt lymphoma, and post-transplant lymphoproliferative disorders (PTLD). Because LMP2 is an intracellular protein, its peptide fragments (such as the immunodominant CLGGLLTMV epitope) are processed and presented on the cell surface in complex with HLA class I molecules, most commonly HLA-A*02:01, HLA-A*24:02, or HLA-A*11:01. This peptide-HLA complex serves as a highly specific target for cellular immunotherapies, including T-cell receptor-engineered T-cell (TCR-T) therapies, chimeric antigen receptor (CAR) T-cell therapies utilizing TCR-mimic (TCRm) antibodies, and bispecific T-cell engagers. Therapeutic candidates like YT-E001 and various TCRm bispecific antibodies (e.g., E38) are designed to recognize this complex to selectively eliminate EBV-positive tumor cells while sparing healthy tissues. However, challenges such as HLA downregulation, epitope mutations, and potential cross-reactivity with self-peptides present significant hurdles in clinical development.
Drugs targeting this complex act by mimicking T-cell receptors (TCRs) or utilizing engineered TCRs to redirect the host immune system, specifically cytotoxic T lymphocytes, to recognize and destroy cells presenting the viral LMP2 peptide on their HLA molecules.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus latent membrane protein 2 peptide-human leukocyte antigen complex (EBV LMP2 peptide-HLA complex).